An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2
z. Cheng, D. Zhang, X. Liu, J. Miao, J. wang, H. Guo, W. Yan, Z. Zhang, S. Lu, N. Zhang, J. Wang, Z. Zhang, W. Liu, Y. Zhang, L. Zhang, J. Dong, N. R. Lemoine, Y. Wang
Abstract
More than one hundred vaccines against SARS-CoV-2 have been developed and some of them have entered clinical trials, but the latest results revealed that these vaccines still face great challenges. Here, we developed a novel cell-based gp96-Ig-secreting chimeric vaccine which is composed of two viral antigens, the RBD of spike protein, and a truncated nucleocapsid protein that could induce epitope-specific cytotoxic T lymphocytes but low antibody response. Syrian hamsters immunized with the cell-based vaccine produced high level of SARS-CoV-2 specific NAbs and specific T cell immunity which could eliminate RBD-truncated N-expressing cells, without the induction of antibody against N protein and other observed toxicity. This study provides a proof of concept for clinical testing of this safe, effective and cost-effective vaccine against SARS-CoV2 infection.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neutralizing antibody-independent immunity to SARS-CoV-2 in hamsters and hACE-2 transgenic mice immunized with a RBD/Nucleocapsid fusion protein
J. Castro, M. Fumagalli, … R. Gazzinelli·bioRxiv·Sep 16, 2021
- PRE-CLINICAL IMMUNE RESPONSE AND SAFETY EVALUATION OF THE PROTEIN SUBUNIT VACCINE NANOCOVAX FOR COVID-19
T. N. M. Tran, B. May, … M. S. Do·bioRxiv·Jul 20, 2021
- A novel chimeric coronavirus spike vaccine combining SARS-CoV-2 RBD and scaffold domains from HKU-1 elicits potent neutralising antibody responses
Veronica P. Zoest, Wen Shi Lee, … Hyon‐Xhi Tan·npj VaccinesPeer-reviewed·Nov 28, 2025
- Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models
J.-G. Park, F. S. Oladunni, … M. Munir·bioRxiv·Jan 8, 2021
- Development and pre-clinical evaluation of Newcastle disease virus-vectored SARS-CoV-2 intranasal vaccine candidate
M. Fernandez-Diaz, K. Calderon, … Salguedo-Bohorqu·bioRxiv·Mar 7, 2021
- Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates